Michelson Diagnostics is led by experts in the field of medical devices, engineering and biomedical photonics.
Jon is co-founder and Chief Executive Officer of Michelson Diagnostics. With over 30 years’ in engineering his prior experience includes Business Director of the Biomedical Group at Sira and a Director of the Smart Optics Faraday Partnership. Jon holds an MA in Physics and Theoretical Physics from the University of Cambridge and is a Fellow of the Institute of Physics. He has filed several patents and published papers and book chapters on OCT.
Alison joined Michelson Diagnostics in 2008 and has over 30 years’ experience in the Accounting sector. She looks after the financial and operational aspects of the business including financial reporting, audits, stock control and management of production, service & support.
Marcel joined Michelson Diagnostics in 2016 and was appointed Chief Software Engineer in October 2017. He has a Masters degree in Electrical Engineering, specializing in Signal Processing, from Technical University of Berlin, providing a strong background in physics, computer science and machine learning.
Matthew (Matt) Jones joined Michelson Diagnostic in 2012 as Production Technician. He has an HNC in Electrical and Electronic Engineering from Northwest Kent College. He was promoted to Service Manage in 2017 and is responsible for managing service support of our growing customer base, working with our network of local service partners internationally. Matt also supervises production of new units.
Craig has been a marketing and business development professional in the medical device industry for over 20 years. He joined MDL to help build the dermatology business in the U.S. focusing on the development of OCT-guided laser applications including the treatment of Basal Cell Carcinoma and Vascular Lesions.
Prior to Michelson, Craig worked in the medical laser industry for both Lumenis and Sciton developing new applications in the fields of Urology, Gastroenterology, ENT, Wound Care, and most recently Dermatology.
Craig started in the device business as a product manager in the Urology speciality after completing a degree in Biochemistry from The University of California at Berkeley and an MBA
Kevin has been an investor in and chairman of Michelson Diagnostics since 2018. Kevin’s career has been in the life science products and the medical devices industry where he has been CEO or chairman of several private and publicly quoted companies. He jointly founded Bioquell plc and helped create the Ferraris Group plc a leading, international cardiorespiratory group.
He is currently chairman of Manchester Imaging Ltd and former chairman of Monica Healthcare Ltd (sold to GE); director and former chairman of Hallmarq Veterinary Imaging Ltd (sold to August Equity); chairman of Crystallon Ltd and Oxford Cryosystems Ltd (sold to Judges Scientific); former chairman of Imorphics (sold to Stryker Corp) and a director of Surface Transforms plc.
His career which started with the purchase of Warne Surgical Products in 1979 and which was sold to Teleflex Inc is described in www.salusinvest.com. Through his consultancy partnership, Salusinvest LP he is a board member of Metrasens Ltd and advises a number of EU and US-listed med-tech companies.
He is a chemical engineer from the University of Leeds and has an MBA from Manchester Business School.
Jon Holmes Jon is co-founder and Chief Executive Officer of Michelson Diagnostics. With over 30 years’ in engineering his prior experience includes Business Director of the Biomedical Group at Sira and a Director of the Smart Optics Faraday Partnership.
Jon holds an MA in Physics and Theoretical Physics from the University of Cambridge and is a Fellow of the Institute of Physics. He has filed several patents and published papers and book chapters on OCT.
Xavier has been a non-executive director of Michelson Diagnostics since 2012. He has broad international experience and spent more than 40 years in the pharmaceutical industry. He served as founder and CEO and President of Galderma, a global dermatology company since 1989 and retired in 2004.
Galderma has revenues in excess of $2 billion p.a. Previous to Galderma he worked for Solvay, Pfizer and Alcon. Mr. Yon serves as a Vice Chairman of the École de Biologie Industrielle de Cergy-Pontoise (French non-profit organisation) (France) and is a director and member of the Supervisory board at Virbac SA.
Mr. Yon holds a degree in Physics, Chemistry and Biology from Sorbonne University, Paris and attended the Advanced Management Program at Harvard University.